SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine, has obtained a patent from the U.S. Patent and Trademark Office for its innovative blood collection device used in fetal sex determination tests.
The patent, numbered 11,932,907, protects the use of push-button blood collection devices for PCR-based fetal sex determination, specifically for the company's SneakPeek Snap products in the United States until 2040.
The newly granted patent also encompasses technology aimed at enhancing the accuracy of fetal sex testing by minimizing the presence of contaminating DNA in maternal blood samples. SneakPeek Snap's blood collection method simplifies the process of obtaining a blood sample at home, requiring consumers to place the device on their arm and press a button, with the sample collection completed in one to four minutes.
Clinical studies have indicated that the SneakPeek Snap device significantly lowers the risk of contamination from external male DNA in maternal blood samples, thereby ensuring a high level of accuracy in determining fetal sex.
Dale Muzzey, PhD, Chief Scientific Officer at Myriad Genetics, expressed that the patent acknowledges the company's novel approach to fetal sex testing using PCR-based techniques with any push-button blood collection device. The patent not only solidifies SneakPeek Snap's exclusivity in the U.S. market but also opens avenues for potential licensing deals with leading suppliers in the field, positioning Myriad Genetics as a strategic partner.
Myriad Genetics offers an array of genetic tests that assist in evaluating disease risk, monitoring disease progression, and informing treatment decisions across various medical specialties. These genetic insights aim to enhance patient care and reduce healthcare costs.
The company's forward-looking statement in the press release indicates an expectation that the SneakPeek Snap patent will offer protection for its products through 2040 and may lead to licensing opportunities with key push-button blood collection device suppliers. However, Myriad also notes that these expectations are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated.
This article is based on a press release statement from Myriad Genetics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.